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Abstract 
 
The main aims of this article are to report the overall and disease-specific survival of 
a consecutive series of patients presenting with oral cancer from 1992 to 2002 and 
relate survival to clinical and pathological factors. The article uses population-based 
age-sex mortality rates in the North-West of England to highlight differences in 
overall and disease-specific survival.  
541 patients with oral squamous cell carcinoma presented to the Regional 
Maxillofacial Unit from 1992 to 2002. Curative treatment favoured radical primary 
surgery, 10% (52) received primary radiotherapy. These patients were on average 8 
years older with more advanced tumours and overall poorer survival at 5 years, 23% 
(SE 7%). The remainder of the results refer to 489 patients who had primary curative 
surgery, 40% (194) of whom received adjuvant radiotherapy.  The overall survival 
(OS) was 56% (SE 2%) and the disease-specific survival (DSS) was 74% (SE 2%). 
There was local recurrence rate of 10% (50) and the loco-regional recurrence rate was 
21% (103). The second primary rate was 7% (35). Survival figures had improved over 
the 10-year period from 63% DSS for the first 4 years of the study (1992-1995) 
compared to 81% for the last 3 years (2000-2002).  In stepwise Cox regression the 
two predictors selected for disease specific survival were pN status and margins (both 
p<0.001).  Age-sex mortality rates for the North-West indicate that 15.0% of the 489 
primary surgery patients might have been expected to die within 5 years if they were 
typical of the general population and the observed difference between all causes and 
oral-cancer specific survival was 18.3%.  
 
These data emphasise the value of disease-specific survival as an indicator of 
successful treatment in a cohort that tends to be elderly, from social deprived 
backgrounds, with life styles and comorbidity that influence overall survival.  
 
 
Word count for abstract 295
 4 
Introduction 
  
UK cancer rates for melanoma, oral cavity, uterus and kidney are increasing. 
1
 From 
1995 to 2004 the number of new diagnoses of oral cancer rose from 3696 to 4769, (i.e. 
from about 64 to 80 cases per million UK population), an increase in age standardised 
incidence of 23%.
  
Since the 1970s survival rates for oral cancer have remained 
constant whilst incidence has increased among younger people. 
2
  
 
Relatively few institutions have reported survival data of their patients with oral 
cancer and this probably in part reflects the diligence required in collecting accurate 
data. Some older papers pre-date the widespread introduction of microvascular 
reconstructive techniques.
3-6
 Reports exist from within other countries such as 
Australia,
7 
Denmark,
8,9,
 Taiwan,
10
 USA
11-14
 Norway,
15
 Japan,
16
 South Korea,
17
 
Germany 
18
 but there is a paucity of data from the UK.  
 
The Regional Maxillofacial Unit in Liverpool has previously published survival data 
on oral and oropharyngeal squamous cell carcinoma 
19-21
  and about the influence of 
pathological features on prognosis.
22,23
 Survival data have also been published in 
relation to blood transfusion and free tissue transfer,
24
 for patients with mandibular 
invasion 
25
  and in respect to adjuvant radiotherapy for patients at an intermediate risk 
of recurrence.
26 
This is the first paper from this Unit to report overall experience in the 
management of oral cancer including primary radiotherapy and primary surgery. 
 
The Unit has advocated radical primary surgery with free tissue transfer 
reconstruction where indicated in the management of oral cancer.
27
 A selective neck 
dissection is performed when depth of tumour invasion exceeds 3 to 4 mm. 
Operations are performed with intention to cure by resection of in excess of a one 
centimetre margin of normal tissue. Post-operative radiotherapy is given as adjuvant 
treatment based on the histopathology of the resection specimen. 
26
 Megavoltage 
external beam radiotherapy is employed, directed at the primary site and draining 
lymphatic apparatus in the neck. The typical regimen uses a three-field method 
including bilateral parallel opposed fields to the primary site and upper neck and, 
when prescribed, a low single anterior neck field. X-rays (5MV) were used in 2 Gray 
daily fractions 5 days per week, with typical doses of 50 to 60 Gray  
 5 
 
Cure and survival is of primary concern for patients 
28,29
 however there are several 
problems with basing outcome exclusively on overall survival. Patients are relatively 
elderly and often have associated comorbidity associated with their life style and 
background. Therefore following oral cancer treatment they can die of other causes 
and have life expectancy of less than five years (5-year survival). From an Oral 
Oncology perspective, successful treatment can be defined by the absence of further 
disease. Overall survival is relatively easy to measure particularly with the assistance 
of national hospital data or links with outside agencies such as the Office for National 
Statistics. However disease specific survival is much more difficult to record 
accurately. It is difficult to maintain accurate follow-up data to confirm the absence of 
oral cancer at the time of death. Death certification is problematic with a tendency 
once diagnosed with oral cancer to record the demise of the patient as an oral cancer 
death.
21
 In addition although loco-regional recurrence or second primary oral tumours 
are usually easily identifiable, it is difficult to completely exclude disseminated spread 
or to account for treatment associated affects which may have had a bearing on 
outcome such as silent aspiration leading to pneumonia. Because of the importance of 
disease specific survival as an outcome parameter the main aim of this article is to 
report the overall and disease-specific survival of a consecutive series of patients 
presenting with oral cancer from 1992 to 2002 and to relate survival to clinical and 
pathological factors. Importantly the paper also uses population-based age-sex 
mortality rates in the North-West to help put differences in overall and disease-
specific survival into perspective. 
 
Methods 
 
Since 1992 all patients diagnosed or treated with Head and Neck cancer in the 
Regional Maxillofacial Unit have routinely had their details entered onto a 
computerised Head and Neck database.  This database includes details of demography, 
clinical status (TNM)) of the tumour, treatment (surgical and radiotherapy), 
pathological stage  (pTNM),  
30 
recurrence (local, regional, locoregional), subsequent 
management and disease status at last visit.  
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The preferred method of treatment was primary surgery to eradicate the tumour and in 
patients with tumours of thickness of more than 3 to 4 millimetres also underwent  
selective neck dissection to appropriately stage the tumour and aid the decision to add 
RT to the treatment plan. . Patients were considered for radiotherapy if they had 
involved margins, extracapsular spread or close margins with nodal metastasis. Over 
the time period of the study there was a shift in dosage from 50 Gy to 60 
Gy .Radiotherapy details were corroborated with the computerised patient records at 
Clatterbridge Centre for Oncology. 
 
The Office of National Statistics supplied death certification details comprising the 
immediate cause of death plus associated factors.  Patient follow-up was until January 
1st 2005 with at least 2 years follow-up for each patient. Four clinicians 
independently attributed cause of death to oral cancer or other causes and a consensus 
was taken. In 10 cases (4% of deaths) there was a 50:50 judgement and further 
discussion between clinicians was required to reach a verdict based on the most recent 
follow-up record and the medical status of the patient. 
 
Recurrence was defined as local (arising only in the oral cavity relative to the primary 
tumour), regional (arising only in the neck) and loco-regional (arising in both primary 
site and neck). The preferred method of confirming recurrence was by biopsy and this 
was done for all patients treated, with a further attempt at cure. Other acceptable ways 
to confirm recurrence were by scanning or by fine needle aspiration cytology. 
 
Statistical method 
 
Office for National Statistics age-sex mortality rates for 2000 for the North-West were 
used to estimate naturally occurring mortality over a 5 year period in the patient 
cohort from the time of surgery. The age groups used were 16-24, 25-34, 35-44, 45-54, 
65-75, 75-84 and 85+ years. Rates were applied year by year to patients so as to 
account for the ageing cohort effect.  
 
Kaplan-Meier methods were used to estimate the disease-specific (DSS) and overall 
survival (OS) by patient groups and the log-rank test was used to compare survival 
curves. Cox regression methods were used to investigate the main independent 
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predictors of survival and linear predictor scores from the regression model were used 
to place patients into five risk groups based on margins and pN status. Because of the 
multitude of testing we regarded p<0.01 as statistically significant. 
 
The link with the Office of National Statistic has ethical approval from the Multi-
Research Ethical Committee (MREC) and the data collection on the Liverpool 
Oncology Database has approval from the Sefton Research Ethics Committee, 
 
Results 
The 1992 to 2002 cohort comprised 541 patients with oral squamous cell carcinoma. 
A total of 489 had primary surgery, 40% (194) with adjuvant radiotherapy, while 52 
had primary radiotherapy. Primary radiotherapy patients were older (median 70 Vs 62 
years), with more advanced tumours (>=4cm: 48% Vs 29%; Clinical T3-4: 50% Vs 
40%; Clinical tN2-3: 16% Vs 6%). Their overall survival rate at 5 years was 23% (SE 
7%).  The rest of this paper relates to the 489 patients with primary surgery.  Overall 
survival at 5 years was 56% (SE 2%), while disease specific survival was 74% (SE 
2%)and loco-regional recurrence-free survival was 76% (SE 2%), Table 1, Figure 1.  
There was local recurrence for 10% of patients (50) and loco-regional recurrence  in  
21% of patients (103). The second primary rate was 7% (35). Most (82%, 400/489) of 
these patients had a neck dissection, 268 unilateral, 129 bilateral and 3 
radical/modified radical. Three-quarters (76%, 373) were treated by free-flap surgery, 
with 260 soft tissue and 113 composite flaps, while one-quarter were treated mainly 
by laser or primary closure including the 89 without neck dissection.  Other 
characteristics of the sample are shown in Table 2.  
 
 
Age-sex mortality rates for the North-West 2000 were applied to the 489 patients to 
estimate the expected naturally occurring mortality within 5 years from surgery. As 
rates for oral cancer mortality in the general population are negligible relative to total 
mortality this expected mortality was assumed to be for deaths other than from oral 
cancer. The calculated expected mortality of these 489 patients within 5 years of 
surgery was 15.0%. The difference between the Kaplan-Meier all-causes and oral-
cancer specific survival at 5 years was 18.3%.  
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The patient factors listed in Table 2 were analysed as to how well they predicted 
survival, and the results of univariate Kaplan-Meier analyses to compare survival 
curves are also shown in Table 2. The strongest univariate predictors of oral cancer 
specific survival were pathological features of the tumour, in particular extra-capsular 
spread and pN status which were strongly inter-related. Age and clinical appearance 
of the tumour were also predictive, as was free-flap surgery and use of adjuvant 
radiotherapy.   
 
In Cox regression modelling (with p<0.01 for entry) to predict disease specific 
survival the first predictor into the regression was extra-capsular spread (at p<0.001), 
and then tumour margins (p<0.001 for its extra contribution to the model, χ2=26.7), 
pN status (p<0.001 for extra, χ2=16.9), age group (p=0.003 for extra, χ2=14.00), 
pstage (p=0.002 for extra, χ2=15.2) and tumour differentiation (p=0.006 for extra, 
χ2=10.3) before extra capsular spread was then forced out of the regression model. 
The final model from these regression analyses is summarised in Table 3. In 
modelling the three initial main predictors only, pN status added significantly 
(p<0.001) to the model comprising extra capsular spread and margins whilst margins 
added significantly (p<0.001) to the model comprising extra capsular spread and pN 
status. However extra capsular spread did not add significantly (p=0.02) to the model 
comprising margins and pN status.  
 
Linear predictor scores from the regression model involving pN and margins were 
used to place patients into five risk groups for the purpose of illustrating the amount 
of discrimination in outcome being achieved by these variables (Figure 2). There is a 
certain logic to these 5 groups if we were to score margins as 0=clear, 1=close, 
2=involved and score pN as 0=pN0, 1=pN1, 2=pN2 as then the 5 risk groups 
represent a combined score of 0, 1, 2, 3 and 4 respectively.  When the regression was 
re-run using the five risk groups the same three additional variables of age group, p 
stage and tumour differentiation were selected into the regression model. Survival by 
p stage alone is shown in Figure 3, whilst survival by ECS and margins is shown in 
Figure 4 whilst survival by ECS alone, margins alone and pN status alone are shown 
in Figures 5 to7. .  
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Cox regression modelling (with p<0.01 for entry) to predict all causes survival the 
first variable into the regression was extra-capsular spread (at p<0.001), and then age 
group (p<0.001 for its extra contribution to the model, χ2=25.0), perineural status 
(p<0.001 for extra, χ2=15.5) and margins (p=0.002 for extra, χ2=12.9). 
 
Age per se was predictive of disease-specific survival (Table 1) and was notably 
worse in those aged 75 years or older.  These older patients comprised more female 
patients (57%, 48/84 Vs 34%, 139/405) and more graded as ASA III or IV (41%, 
31/75 Vs 18%, 66/359). There were more pT3-4 tumours (51%, 43/84 Vs 37%, 
150/405), and extra-capsular spread (27%, 23/84 Vs 19%, 78/405) but fewer N 
positive tumours (18%, 15/84 Vs 29%, 119/404).  Otherwise those aged 75 and over 
were quite similar to younger patients in regard to the other variables described in 
Table 1 except that fewer had free flap surgery (64%, 54/84 Vs 79%, 319/405), neck 
dissection (71%, 60/84 Vs 84%, 340/405) and adjuvant radiotherapy (30%, 25/84 Vs 
42%, 169/405).  
 
Year group (1992-5, 1996-9, 2000-2) was also predictive of disease-specific survival 
at p<0.001 (χ2=19.2) after adjusting for the variables in Table 2, indicating a halving 
in mortality from 1992-5, with a hazard ratio (relative risk of death) of 0.4 (95% CI 
0.3 to 0.7) for both 1996-9 and 2000-2 relative to 1992-5. The rate of local-only 
recurrence also fell (17%, 27/156 Vs 7%, 14/196 Vs 7%, 9/137) as did the rate of any 
loco-regional recurrence (30%, 47/156 Vs 18%, 35/196 Vs 15%, 21/137). Clinically, 
there was a progressive increase in patients presenting with smaller tumours under 
2cm (14%, 25%, 37%), this also being reflected in more clinical T1 (17%, 25%, 35%), 
pT1  (21%, 28%, 35%) and Pstage 1 tumours (19%, 24%, 32%). Fewer had perineural 
invasion (33%, 24%, 20%) or positive nodes (41%, 35%, 31%). The groups were 
more similar in regard to other variables in Table 2 except for an increase towards 
treating by laser/primary closure (13%, 22%, 38%) and for not doing a neck 
dissection (11%, 18%, 27%).  The percentage having radiotherapy changed little over 
time (46%, 37%, 37%) but of those receiving radiotherapy the percentage having 
60Gy or more did increase (15%, 50%, 82%). Five-year disease specific survival for 
less than 60Gy was 59% (SE 5%) and for 60Gy and more was 63% (SE 6%). 
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Though both free-flap surgery and adjuvant radiotherapy were predictive of worse 
outcome in univariate analyses both these reflect the underlying pathology of the 
patient condition and neither variable was a significant predictor when added to the 
model described in Table 3 (free-flap: p=0.84, hazard ratio 0.9 (95%CI 0.5 – 1.9); 
radiotherapy: p=0.31, hazard ratio 0.8 (95%CI 0.5 – 1.3).  
 
 
Discussion 
 
This is the first paper from this Unit to focus exclusively on oral cancer and compare 
survival outcome with age-sex mortality rates for the North-West. Our experience in 
oropharyngeal cancer will be reported in a separate article (in preparation). The 
findings are strengthened by the consecutive nature of the cohort and an intention 
throughout the study period for curative primary surgery. It is a larger series than we 
have previously published (all our references in introduction) with longer patient 
follow-up. In recognition of the need for close follow-up 
31
 and limitations of using 
Cancer Registry data,
2
 there has been very careful documentation of disease specific 
status. Using our oncology database we were able to take note of last clinic 
appointments and of recurrence status throughout each patient’s follow-up. The link 
with the Office of National Statistic allowed for cross-reference between hospital 
records and official date and cause of death. Four clinicians independently ascribed 
the cause of death and consensus was achieved in the relatively few cases where there 
was disagreement. The comparison with age-sex mortality rates for the North-West of 
England has allowed for closer inspection as to the difference between all cause and 
disease specific mortality. It is recognised that the data only represents the experience 
of one regional unit in the North-West of England. This may not be typical because 
the immediate catchment population live in a particularly deprived area of the UK. 
32
 
In this article we report on all oral cancer sites and it is intended that further work will 
include in-depth analyses of particular sub-sites such as the cheek (buccal carinoma). 
 
Although it is often stated that survival figures for oral cancer are not improving our 
data shows that the disease-specific survival following primary surgery was 74%. 
There was an improvement in survival figures over the 10 year period of the study 
from 63% DSS for the first 4 years of the study (1992-1995) compared to 81% for the 
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last 3 years (2000-2002). The overall 5-year survival was 56% improving from the 
first 4 years of the study (46%) to the last 3 years (64%). The difference in DSS and 
overall survival reflects issues around associated co-morbidity and comparison with 
age-sex mortality rates for the North-West of England has shown that a substantial 
proportion of non oral cancer deaths would be expected by 5 years in this cohort. 
It is difficult in a retrospective study to clearly identify reasons for the improvement 
in survival over time in our cohort. The earlier group had similar characteristics in 
terms of gender, age site and pathology. However the earlier patients in the series 
tended to have larger tumours (reflected in pT stage) and have free tissue 
reconstruction. There were similar clear margin rates yet the earlier group were more 
prone to local recurrence. The indication that a higher proportion of patients were 
being seen with earlier disease since 1996 is encouraging and might reflect better oral 
cancer awareness and faster referral processes. It is unlikely to reflect a change in 
referral patterns from clinicians in the Mersey Region as here is a long established 
referral process to the Regional Unit base on a hub and spoke configuration with all 
oral cancers being referred from the spokes on diagnosis. Another factor behind 
improved survival might be better medical management with improvements in 
managing comorbidity, in comorbidity however sufficient data for a robust comment 
is unfortunately lacking in this retrospective analysis. Inclusion of cormorbidity 
indices such as the ACE-27 in the future will perhaps allow a better indication of the 
changes in associated illness over time of patients with oral cancer.  It was notable 
that patients aged 75 and over had a worse overall and disease specific survival. There 
are many issues potentially associated with this such as worse comorbidity and their 
ability to withstand radical treatment including adjuvant radiotherapy. In our cohort, 
patients 75 or over were less likely to have adjuvant radiotherapy. 
  
Several features of the primary tumour had significant bearing on outcome. The main 
clinical predicators were margins, pattern of invasion, tumour differentiation, pTstage, 
perineural invasion, presence positive nodes and of extracapsular spread. Our results 
confirm the well-established relationship between cervical node metatasis and 
reduced rates of survival. In our series the proportion of those having a neck 
dissection has decreased over time and mostly reflects a change in practice in favour 
of less free flap reconstructions in selected patients. Although primary closure or laser 
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was used more frequently in recent years we have not noticed an increase in involved 
margins, local or regional recurrence rates, nor a fall in our survival rates.  
 
We postulate that 15.0% of patients would be expected to die within 5 years if they 
were typical of the general population and this compares to the observed difference 
between all-causes and oral-cancer specific survival for the 489 oral cancer patients of 
18.3%. This emphasises the risk of death in oral cancer of recurrence in the first 12 to 
24 months and emphasises the poor prognosis, recurrence confers following ‘radical’ 
primary treatment. Of those patients who do not get recurrence their life expectancy at 
5 years is similar to their unaffected counterparts and this reflects geographical and 
life style factors. 
 
It is difficult to compare our outcomes directly with others because of variations in 
case mix, selection for treatment and presentation of outcome data. An indication of 
how our cohort compares to published literature is given in Table 5.  If one looks at 
the figures from the UK, the results for the patients treated with primary radiotherapy 
had DSS of 64% and 55% and OS of 37% and 43% respectively. In a series reported 
by Langdon et al
3
 in which the majority of patients were treated with primary 
radiotherapy (73% of the cohort) the OS was as low as 33% with no figures reported 
for DSS. It is also interesting to note that the more up to date reports show better 
survival figures. Memorial Sloan Kettering have reported their improving oral cancer 
survival figures which very much reflect our reported experience in this study. 
33
 
(Shaw et al 1999) 33 
 
 
These survival figures represent the standard practice in the Regional Maxillofacial 
Unit in Liverpool. The improved survival figures and better local and regional control 
of the disease are welcome and confirm the benefit in the management of this disease 
by primary surgery compared to primary radiotherapy. We have shown that a more 
conservative approach to the primary site and the neck has not compromised our 
results and leave more options for the effective management of recurrence and further 
options for the high percentage of second head and neck primary tumours. 
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Table 1. Recurrence-free, disease-specific and all-causes 5 year Kaplan-Meier 
survival for 489 oral cancer patients by P stage 
 
  5 year Kaplan-Meier % survival (SE)   
 N of patients Loco-regional 
Recurrence-free 
Disease-specific All-causes 
P stage 1 121 92 (3) 96 (2) 76 (4) 
P stage 2 91 80 (4) 82 (4) 68 (5) 
P stage 3 56 78 (6) 78 (6) 65 (7) 
P stage 4 21 65 (4) 57 (4) 37 (4) 
TOTAL 489 76 (2) 74 (2) 56 (2) 
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Table 2. Kaplan-Meier survival analyses for 489 oral cancer patients  
 
Table gives 2 and 5 year Kaplan-Meier survival rates (SE) .  
 
   Disease-specific survival Overall survival 
  
Patients 2yr 5yr 
Log rank 
test 
2yr 5yr 
Log rank 
test 
 TOTAL 489 79 (2) 74 (2)  70 (2) 56 (2)  
Year 1992-5 156 69 (4) 63 (4) 
χ2=12.7 
p=0.002 
59 (4) 46 (4) 
χ2=13.7 
p=0.001 
 1996-9 196 84 (3) 79 (3) 76 (3) 60 (4) 
 2000-2 137 84 (4) 81 (4) 74 (4) 64 (5) 
Gender Male 302 81 (2) 77 (3) χ2=1.5 
p=0.23 
72 (3) 45 (3) χ2=0.5 
p=0.50  Female 187 76 (3) 70 (4) 67 (3) 58 (4) 
Age <55 140 84 (3) 79 (4) 
χ2=13.9 
p=0.003 
79 (4) 67 (4) 
χ2=33.2 
p<0.0001 
 55-64 138 80 (4) 75 (4) 74 (4) 60 (4) 
 65-74 127 81 (4) 79 (4) 69 (4) 52 (5) 
 75+ 84 64 (6) 56 (6) 51 (6) 37 (6) 
Tumour site Buccal 93 75 (5) 68 (5) 
χ2=4.9 
p=0.30 
69 (5) 50 (5) 
χ2=5.2 
p=0.27 
 Lower gum 56 82 (6) 76 (6) 71 (6) 52 (7) 
 Tongue (ant 2/3) 144 81 (3) 78 (4) 72 (4) 64 (4) 
 Floor of Mouth 162 81 (3) 77 (4) 70 (4) 56 (4) 
 Other 34 68 (8) 63 (9) 62 (8) 44 (9) 
Tumour size <2 cm 116 95 (2) 93 (2) 
χ2=31.9 
p<0.0001 
87 (3) 74 (4) 
χ2=26.0 
p<0.0001 
 2-3 cm 224 77 (3) 73 (4) 69 (3) 54 (3) 
 4+ cm 137 69 (4) 61 (4) 58 (4) 44 (4) 
Clinical T stage Tis/1 123 95 (2) 93 (2) 
χ2=34.1 
p<0.0001 
88 (3) 76 (4) 
χ2=32.2 
p<0.0001 
 2 175 77 (3) 74 (4) 68 (4) 57 (4) 
 3 47 72 (7) 66 (8) 60 (7) 48 (7) 
 4 144 70 (4) 61 (5) 61 (4) 41 (4) 
Clinical N stage 0 354 84 (2) 80 (2) 
χ2=23.6 
p<0.0001 
76 (2) 62 (3) 
χ2=24.2 
p<0.0001 
 1 103 69 (5) 62 (5) 57 (5) 40 (5) 
 2+ 31 58 (9) 53 (10) 52 (9) 37 (9) 
ASA I 115 86 (3) 84 (4) 
χ2=5.1 
p=0.17 
80 (4) 77 (4) 
χ2=30.5 
p<0.0001 
 II 222 77 (3) 71 (3) 70 (3) 52 (4) 
 III/IV 97 76 (5) 71 (5) 61 (5) 39 (5) 
 Unknown 55 77 (6) 72 (7) 66 (6) 54 (8) 
Free-flap surgery Yes 373 75 (2) 70 (3) χ2=15.9 
p<0.0001 
66 (2) 51 (3) χ2=10.4 
p=0.001  No 116 93 (3) 88 (4) 82 (4) 72 (5) 
Neck dissection Yes 400 76 (2) 70 (2) χ2=14.0 
p<0.0001 
68 (2) 52 (3) χ2=9.7 
p=0.002  No 89 93 (3) 91 (3) 82 (4) 76 (5) 
Adjuvant Yes 194 68 (4) 59 (4) χ2=34.4 
p<0.0001 
61 (4) 42 (4) χ2=26.3 
p<0.0001 radiotherapy No 295 87 (2) 84 (2) 76 (2) 65 (3) 
Tumour Poor 49 57 (7) 48 (8) 
χ2=34.0 
p<0.0001 
53 (7) 29 (7) 
χ2=24.6 
p<0.0001 
differentiation Moderate 286 76 (3) 70 (3) 66 (3) 53 (3) 
 Well 139 92 (2) 89 (3) 81 (3) 68 (4) 
Pattern  Favourable 146 94 (2) 91 (3) χ2=28.4 
p<0.0001 
83 (3) 72 (4) χ2=17.5 
p<0.0001 of invasion Unfavourable 327 71 (3) 65 (3) 63 (3) 47 (3) 
Margins Clear >5mm 237 91 (2) 88 (2) 
χ2=50.9 
p<0.0001 
82 (2) 66 (3) 
χ2=34.2 
p<0.0001 
 Close <5mm 170 72 (4) 66 (4) 65 (4) 53 (4) 
 Involved 82 58 (6) 49 (6) 45 (6) 35 (5) 
pT stage Tis,1 134 96 (2) 95 (2) 
χ2=47.8 
p<0.0001 
89 (3) 75 (4) 
χ2=39.8 
p<0.0001 
 2 162 78 (3) 73 (4) 70 (4) 59 (4) 
 3 30 67 (9) 58 (10) 57 (9) 46 (10) 
 4 163 67 (4) 61 (4) 57 (4) 39 (4) 
pN 0 310 91 (2) 87 (2) 
χ2=104.7 
p<0.0001 
81 (2) 68 (3) 
χ2=72.4 
p<0.0001 
 1 72 73 (6) 68 (6) 65 (6) 49 (6) 
 2-3 107 48 (5) 40 (5) 42 (5) 26 (5) 
P stage 1 121 97 (2) 96 (2) 
χ2=71.0 
p<0.0001 
89 (3) 76 (4) 
χ2=62.4 
p<0.0001 
 2 91 86 (4) 82 (4) 79 (4) 68 (5) 
 3 56 85 (5) 78 (6) 77 (6) 65 (7) 
 4 221 64 (3) 57 (4) 54 (3) 37 (4) 
Perineural  No 364 85 (2) 81 (3) χ2=33.1 
p<0.0001 
76 (2) 63 (3) χ2=33.1 
p<0.0001 invasion Yes 125 61 (5) 55 (5) 52 (4) 35 (4) 
Extra capsular  No ECS 388 87 (2) 83 (2) χ2=100.7 
p<0.0001 
79 (2) 64 (3) χ2=84.4 
p<0.0001 spread ECS 101 45 (5) 37 (6) 37 (5) 24 (4) 
Positive nodes No  314 90 (2) 87 (2) χ2=76.0 
p<0.0001 
80 (2) 67 (3) χ2=52.3 
p<0.0001  Yes 175 58 (4) 52 (4) 52 (4) 36 (4) 
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Table 3. Final model of independent predictors of disease specific survival for 489 
patients with neck dissection using multi-variable Cox regression 
 
 Hazard ratio (relative risk of 
death) 
95% CI of Hazard ratio 
pN status:   
   pN0 Relative to ‘pN0’  
   pN1 2.5 1.2 - 5.1 
   pN2-3 3.4 2.0 - 5.8 
Margins:   
   Clear Relative to ‘clear’  
   Close 2.3 1.5 - 3.6 
   Involved 2.8 1.7 - 4.7 
Age group:   
   <55 Relative to ‘<55 years’  
   55-64 1.5 0.9 - 2.5 
   65-74 1.6 0.9 - 2.6 
   75+ 3.4 2.0 - 5.8 
Pstage   
1 Relative to ‘stage 1’  
2 3.7 1.4 - 10.2 
3 1.5 0.4 - 5.0 
4 3.8 1.4 -10.1 
Tumour differentiation:   
Well Relative to ‘Well’  
Moderate 2.8 1.4 - 5.5  
Poor 1.4 0.8 - 2.4 
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Table 4. Recurrence by Tumour site 
 
  
Local only 
Regional 
only 
Local and 
regional 
Any loco-
regional* 
Distant 
 N % n % n % n % n % n 
Buccal 93 19 18 3 3 6 6 29 27 1 1 
Lower gum 56 11 6 2 1 5 3 18 10 4 2 
Tongue anterior 2/3rds 144 6 8 8 11 3 4 16 23 4 6 
Floor of Mouth 162 6 10 9 15 2 4 18 29 5 8 
Other 34 24 8 18 6 0 0 41 14 0 0 
TOTAL 489 10 50 7 36 3 17 21 103 3 17 
  
* P=0.004, Chi-squared=15.4,  4 df. 
 
 21 
 
 
Table 5 Survival data for oral cancer 
 
Author Year Institute No 
Patients 
% patients 
treated 
with 
surgery 
% DSS 
(5 
years)  
% OS 
(5 
years) 
Langdon  1977 London, UK 131 27 - 33 
Wildt 1989 Arrhus, Denmark 267 60 - 44 
Lindelov 1990 Copenhagen, Denmark 304 26 41  
Loree 1990 Memorial Sloan Kettering, USA 398 100 - 57 
Tytor 1990 Bergen, Norway 176 76 53 28 
Jones 1993 Liverpool, UK 126 0 64 37 
Shingaki 1995 Niigata, Japan 61* 100 87 80 
Turner  1996 Manchester, UK 333 0 55 43 
Chen  1999 Southern Taiwan 496 65 - 32 
Koo 2006 Soeul, South Korea 127 100 76 71 
Kessler 2008 Erlangen, Germany 128 100 83 69 
Current paper 2008 Liverpool, UK 489 100 74 56 
 
NB * denotes stage I and II only 
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 Figure 1. All causes and disease specific survival 
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Figure 2 Disease specific survival for 489 patients with oral tumours by pN status and 
closeness of margins.  
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Groups (patients in cohort) 
                A (n=180): Clear Margins & pN0  
  B (n=122): Clear margins & pN1 OR close margins & pN0 
  C (n=97) : Clear margins & pN2-3 OR close margins & pN1 OR involved margins & pN0 
  D (n=56) : Close margins & pN2-3 OR involved margins & pN1 
  E (n=34) :  Involved margins & pN2-3 
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Figure 3 Disease specific survival for 489 patients with oral tumours by p stage  
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Groups (patients in cohort) 
               P stage 1 (n=121), P stage 2 (n=91), P stage 3 (n=56), P stage 4 (n=221) 
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Figure 4 Disease specific survival for 489 patients with oral tumours by extra-capsular 
spread and margins.  
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                A (n=210): Clear Margins & no ECS   
  B (n=130): Close Margins & no ECS   
  C (n=48):    Involved Margins & no ECS   
  D (n=27):   Clear Margins & ECS   
  E (n=40:     Close Margins & ECS   
  F (n=34):     Involved Margins & ECS  
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Figure 5 Disease specific survival for 489 patients with oral tumours by extra-capsular 
spread. 
 
No ECS
ECS
Months from operation
60483624120
C
u
m
u
la
ti
v
e
 S
u
rv
iv
a
l
100
80
60
40
20
0
 
 
 
 27 
Figure 6 Disease specific survival for 489 patients with oral tumours by involvement 
of margins. 
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Figure 7 Disease specific survival for 489 patients with oral tumours by pN status 
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